|Bid||56.56 x 1000|
|Ask||56.58 x 800|
|Day's Range||56.37 - 58.00|
|52 Week Range||45.58 - 59.00|
|Beta (5Y Monthly)||0.24|
|PE Ratio (TTM)||22.14|
|Earnings Date||Feb 07, 2022 - Feb 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||50.57|
Subscribe to Yahoo Finance Plus to view Fair Value for QGENLearn more
Qiagen closed higher Friday after the diagnostics company reaffirmed the efficacy of its PCR tests against the new Covid variant which scrambled stock markets on Friday. Qiagen (ticker: QGEN) said it assessed its SARS-CoV-2 PCR tests against the new genetic mutations of the variant, known by its scientific name, B.1.1.529. “We are pleased to report that the emergence of this new variant of concerns, as has been the case with other variants, has had no impact on the effectiveness of our SARS-CoV-2 PCR tests,” said Davide Manissero, chief medical officer at Qiagen.
HILDEN, Germany & GERMANTOWN, Maryland, November 26, 2021--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced its polymerase chain reaction (PCR) tests remain accurate and effective in detecting SARS-CoV-2 infections in light of the emergence of a new variant of concern detected in South Africa.
VENLO, Netherlands & HILDEN, Germany, November 08, 2021--QIAGEN commits to reduce carbon emissions by setting science-based target to reach net zero by 2050